Avagenesis Announces Advisor and Private Placement to BioLASCO's Colin Chen

Calgary, Alberta (FSCwire) - Avagenesis Corp. (TSXV: VVA) (“Avagenesis” or “Company”) is pleased to announce the appointment of Mr. Colin Chen, Chairman and CEO of BioLASCO Taiwan Co., Ltd (“BioLASCO”), as an advisor. Mr. Colin Chen will also complete a non-brokered private placement of US$100,000 for Avagenesis common shares (the “Shares”) at a price of CAD$0.25 per Share.

"Avagenesis has an innovative cell bioprocessing system that will revolutionize and standardize the processing and study of important adipose tissue cell populations, that are under intensive academic and clinical research in stem cell biology, medicine and cell therapy globally." stated Colin Chen, “I am pleased to assist with Avagenesis and to connect them with the top medical thought leaders for stem cell translational medicine in Asia."

“We are very pleased to welcome Colin Chen as our Advisor,” stated Norman Tsui, CEO of Avagenesis.  “BioLASCO is one of the most respected names in Asia for research animals, as a technology licensee of Charles River Laboratories (NYSE: CRL), and also as a distributor of The Jackson Laboratory in Taiwan.”

The non-brokered private placement is subject to TSX Venture Exchange (“Exchange”) final acceptance.  All Shares issued under the private placement are subject to a hold period expiring four months and one day from the date of issuance.

About BioLASCO Taiwan Co., Ltd.

BioLASCO is the leading and largest supplier of the highest quality laboratory animals for Taiwan, China and South-East Asia.  It is also a supplier of surgical services and bio-material, a contract research organization and influential designer of animal facilities.  BioLASCO is a technology licensee of Charles River Laboratories (NYSE: CRL) for the production of international standardized SPF Laboratory small animals in Taiwan.  BioLASCO applies the most advanced technology and creates facilities to monitor and maintain animal genetic, microbiological, environmental, and growth/physiological traits to ensure that animal quality meets international standards. BioLASCO is fully accredited with AAALAC International.

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of licensed cell isolation medical technologies for use in regenerative medical aesthetics, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, hepatic disease and kidney disease.

Neither the TSX Venture Exchange nor their respective regulation services providers (as that term is defined in their respective policies) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", “likely”, "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Further Information

For further information, please contact:

Avagenesis Corp.

Alan Tam, CPA, CA

Chief Financial Officer

Telephone: (604) 377-7575

To follow Avagenesis Corp. on your favorite social media platform or financial websites, please click on the icons below.

Maximum News Dissemination by FSCwire. http://www.fscwire.com

Copyright © 2016 Filing Services Canada Inc.